vaccinolog
begin
centuri
andrea
wack
rino
rappuoli
today
main
challeng
vaccinologist
includ
improv
vaccin
yet
undef
pathogen
rapid
identif
respons
emerg
diseas
success
intervent
chronic
diseas
ongo
immun
respons
insuffici
revers
genet
revers
vaccinolog
use
gener
rapidli
new
vaccin
strain
mine
whole
genom
search
promis
antigen
ration
design
adjuv
becom
possibl
result
discoveri
receptor
recogn
microbi
pattern
lead
dendrit
cell
activ
antigenload
dendrit
cell
dna
nake
formul
viral
form
deliveri
system
use
maxim
immun
respons
although
work
easi
vaccin
alreadi
complet
hope
combin
conceptu
technic
innov
enabl
develop
complex
sophist
vaccin
futur
although
erad
smallpox
poliomyel
hope
come
year
mark
two
import
mileston
medic
histori
face
unpreced
success
new
pathogen
jump
speci
barrier
infect
human
frustrat
deriv
inabl
control
devast
diseas
hiv
malaria
tuberculosi
review
cover
recent
progress
vaccinolog
figur
larg
result
dramat
technic
innov
reach
clinic
well
huge
challeng
pose
old
new
pathogen
face
us
three
big
killer
pathogen
heavili
afflict
global
health
hiv
mycobacterium
plasmodium
wherea
latter
two
repres
longterm
companion
human
speci
hiv
viru
spread
human
popul
year
ago
nonhuman
primat
origin
fact
recent
emerg
diseas
go
back
anim
reservoir
infect
human
close
contact
hunt
farm
live
anim
market
food
process
prepar
consumpt
exampl
ebola
viru
three
outbreak
appear
human
popul
nine
time
sinc
outbreak
result
handl
dead
gorilla
chimpanze
duiker
turn
thought
infect
unknown
natur
host
variant
creutzfeldtjacob
diseas
reach
popul
food
chain
render
sheep
cow
carcass
fed
cow
subsequ
consum
human
sever
acut
respiratori
syndrom
sar
coronaviru
sequenc
earliest
identifi
case
ident
found
palm
civet
raccoon
dog
anim
market
farm
strongli
suggest
anim
origin
diseas
rapidli
chang
ecosystem
human
behavior
everincreas
densiti
human
farm
anim
popul
close
vicin
poverti
high
degre
mobil
mani
factor
contribut
frequent
occurr
often
rapid
dissemin
new
diseas
anoth
exampl
arriv
persist
west
nile
viru
usa
probabl
result
increas
mobil
except
broad
host
rang
climat
chang
among
reemerg
diseas
past
year
diphtheria
cholera
mention
well
frequent
appear
multidrugresist
bacteria
case
anthrax
infect
result
deliber
releas
case
influenza
concern
advent
new
pandem
fuell
report
human
infect
avian
viru
strain
h
stand
hemagglutinin
n
neuraminidas
two
major
surfac
glycoprotein
viru
lead
death
http
wwwwhointcsrdiseaseavian
influenzaen
third
time
space
year
previou
outbreak
infect
avian
flu
virus
caus
diseas
death
human
avian
strain
caus
infect
human
world
popul
expos
strain
immunolog
avian
flu
strain
new
surfac
glycoprotein
would
meet
possibl
intervent
point
vaccin
improv
schemat
view
pathogenor
vaccineinduc
immun
respons
vaccin
pathogen
cross
epitheli
barrier
taken
antigenpres
cell
dc
interact
pattern
recognit
receptor
prr
agonist
activ
dc
result
increas
antigen
present
cytokin
product
costimul
cell
recogn
antigen
present
dc
activ
cognat
interact
prime
cell
b
cell
activ
b
cell
result
clonal
expans
antibodi
product
dc
activ
also
lead
inhibit
regulatori
effect
treg
cell
fulli
activ
cell
target
tumor
cell
pathogeninfect
cell
letter
ai
indic
process
improv
vaccin
lead
effici
immun
respons
site
administr
influenc
type
immun
respons
enabl
usag
lower
vaccin
dose
b
particul
antigen
taken
easili
macrophag
dc
solubl
antigen
c
tlr
agonist
immunostimul
bind
prr
increas
activ
dc
dc
matur
load
antigen
vitro
effici
vaccin
e
dna
vaccin
lead
effici
antigen
present
mhc
class
crosspresent
antigen
mhc
class
host
dc
facilit
vaccin
antigenload
dc
undergo
delay
apoptosi
f
cytokin
ad
protein
dna
form
natur
adjuv
g
recruit
nk
cell
earli
sourc
cytokin
h
vaccin
break
toler
suppress
effect
treg
cell
overcom
resist
provid
exist
immun
could
rapidli
expand
avian
strain
develop
effici
mean
humantohuman
transmiss
devast
pandem
aris
could
ensu
note
howev
older
studi
found
seropreval
rate
avian
flu
strain
among
chines
rural
popul
virus
avian
strain
thu
might
fact
qualiti
surveil
rather
frequenc
outbreak
increas
past
year
howev
contact
human
pathogen
anim
reservoir
like
intensifi
consequ
emerg
reemerg
diseas
occupi
vaccinologist
frequent
futur
one
import
futur
challeng
respond
promptli
emerg
diseas
mention
strike
exampl
rapid
reaction
case
sar
outbreak
genom
sequenc
publicli
avail
less
month
viru
identifi
enabl
speedi
develop
diagnost
tool
well
identif
recombin
express
target
vaccin
therapeut
agent
influenza
viru
addit
annual
definit
relev
strain
includ
vaccin
follow
season
world
health
organ
close
monitor
case
avian
flu
inform
see
world
health
organ
websit
indic
prototyp
vaccin
strain
develop
apart
almost
complet
lack
protect
popul
addit
threat
avian
flu
isol
kill
embryon
egg
tradit
viru
growth
substrat
use
influenza
vaccin
product
problem
solv
owe
discoveri
year
ago
influenza
viru
gener
entir
transfect
dna
revers
genet
particular
case
webbi
et
al
use
polymeras
chain
reactionbas
mutagenesi
replac
hemagglutinin
cleavag
site
shown
caus
high
pathogen
strain
sequenc
nonpathogen
strain
vero
cell
transfect
plasmid
encod
neuraminidas
mutat
hemagglutinin
circul
strain
togeth
plasmid
encod
remain
protein
laboratoryoptim
strain
result
vaccin
strain
success
grown
egg
shown
nonpathogen
stabl
thu
use
revers
genet
enabl
rapid
product
refer
vaccin
viru
respons
emerg
new
influenza
variant
addit
revers
genet
use
farreach
vaccin
strategi
construct
consensu
strain
express
conserv
amino
acid
sequenc
one
version
surfac
glycoprotein
addit
immunoenhanc
molecul
cytokin
much
research
effort
also
invest
develop
improv
cell
cultur
system
replac
complet
use
embryon
egg
vaccin
product
would
render
product
process
flexibl
control
sever
report
address
question
stretch
avail
suppli
vaccin
dose
case
shortag
face
pandem
two
studi
indic
intraderm
rather
intramuscular
applic
genom
revolut
open
complet
new
approach
vaccin
discoveri
pathogen
grow
vitro
avail
genom
sequenc
enabl
develop
recombin
vaccin
carri
hepat
b
viru
hbv
underway
hepat
c
regard
bacteria
group
b
meningococcu
pose
insurmount
obstacl
convent
vaccinolog
approach
eventu
overcom
mine
inform
sequenc
genom
total
potenti
vaccin
candid
predict
comput
analysi
express
test
immunogen
candid
clinic
trial
genomebas
approach
call
revers
vaccinolog
use
routin
vaccin
develop
major
tool
quest
vaccin
pneumococcu
group
b
streptococcu
chlamydia
see
also
updat
recent
genom
sequenc
plasmodium
falciparum
main
vector
anophel
gambia
spark
new
hope
effici
vaccin
malaria
rodent
model
diseas
subtract
cdna
techniqu
use
identifi
gene
express
preerythrocyt
stage
parasit
plasmodium
mutant
defici
one
gene
block
earli
liverstag
develop
subsequ
stage
therefor
lead
diseas
sporozoit
use
genet
attenu
vaccin
mice
confer
longlast
stagespecif
protect
promis
exampl
molecular
approach
employ
ration
design
new
vaccin
anoth
exampl
encourag
progress
toward
malaria
vaccin
report
alonso
et
al
describ
phase
iib
trial
subunit
vaccin
consist
recombin
protein
express
yeast
compos
carboxytermin
p
falciparum
circumsporozoit
protein
hbv
surfac
antigen
fusion
protein
togeth
unfus
hbv
surfac
antigen
protein
form
particl
final
vaccin
formul
includ
adjuv
oil
water
emuls
contain
immunostimul
monophosphoryl
lipid
mpl
quillaja
saponaria
fraction
previous
shown
inde
cell
respons
epitop
contain
vaccin
correl
protect
infect
diseas
trial
children
vaccin
show
efficaci
prevent
clinic
episod
sever
episod
respect
past
ten
year
chang
vision
immun
respons
pathogen
becom
clear
degre
type
antigenspecif
clonal
b
cell
respons
acquir
immun
depend
crucial
prior
action
ancient
system
pathogen
detect
innat
immun
system
reli
activ
antigenpres
cell
dendrit
cell
dc
upon
recognit
pattern
common
virus
bacteria
larg
absent
mammal
discoveri
involv
pattern
recognit
receptor
among
tolllik
receptor
tlr
repres
import
subgroup
immuneenhanc
molecul
adjuv
longer
consid
alchemist
immunologist
dirti
secret
becom
amen
ration
design
provid
huge
potenti
manipul
immun
respons
differ
tlr
agonist
elicit
differ
type
immun
respons
review
futur
adjuv
might
abl
tailor
immun
respons
optim
protect
given
pathogen
induc
fact
number
clinic
trial
involv
tlr
agonist
new
adjuv
ever
increas
tabl
adjuv
function
nonmethyl
cytidinephosphateguanosin
cpg
sequenc
frequent
microb
underrepres
human
agonist
extens
demonstr
anim
model
current
test
sever
clinic
trial
cpg
coadminist
licens
hbv
flu
vaccin
combin
lead
increas
antibodi
titer
increas
interferong
ifng
product
compar
respons
vaccin
alon
addit
effect
cpg
oligonucleotid
appear
promot
affin
matur
result
higher
overal
affin
vaccinespecif
antibodi
pool
similarli
agonist
mpl
shown
past
enhanc
immun
respons
hbv
vaccin
human
addit
malaria
subunit
vaccin
mention
licens
melanoma
vaccin
contain
mpl
anoth
experiment
vaccin
includ
agonist
describ
section
synthet
vaccin
activ
dc
increas
abil
process
present
antigen
attract
activ
cell
cytokin
secret
consequ
sever
cytokin
hostpathogen
interact
tabl
human
tlr
agonist
use
adjuv
vaccin
formul
clinic
trial
licens
vaccin
known
current
test
adjuv
function
mention
way
innat
immun
system
activ
influenc
type
ensu
acquir
immun
respons
martinfontecha
et
al
show
abil
adjuv
elicit
type
respons
depend
crucial
recruit
ifng
product
natur
killer
nk
cell
indic
possibl
mechan
way
adjuv
direct
type
adapt
immun
respons
induc
downstream
anoth
vaccin
approach
use
heat
shock
protein
bind
specif
activ
dendrit
cell
load
endogen
peptid
purifi
tumor
cell
function
combin
antigen
deliveri
system
adjuv
main
target
adjuv
dc
logic
step
evalu
direct
use
vaccin
despit
laborintens
necess
individu
cell
cultur
patient
approach
attract
approach
fail
instanc
therapeut
vaccin
hiv
cancer
patient
hiv
patient
treat
autolog
dc
load
autolog
inactiv
hiv
virusspecif
respons
induc
plasma
viral
load
reduc
result
close
reflect
previou
find
similar
vaccin
rhesu
macaqu
except
lack
induct
neutral
antibodi
human
studi
dc
vaccin
also
test
varieti
cancer
treatment
studi
compar
immunogen
dc
transfect
cytopath
noncytopath
viral
rna
former
regimen
shown
effici
induc
protect
immun
respons
suggest
reprocess
die
dc
endogen
antigenpres
cell
enhanc
immunogen
either
addit
danger
signal
trigger
cell
damag
increas
level
crosspresent
endogen
dc
mechan
might
work
mycobacterium
infect
macrophag
apoptosi
shown
enhanc
crosspresent
bystand
dc
interestingli
follow
fraction
cytoplasm
die
cell
uric
acid
identifi
highli
effici
endogen
danger
signal
enhanc
immunogen
might
explain
result
high
expect
associ
dna
vaccin
result
promis
data
obtain
mice
somewhat
temper
disappoint
earli
result
dna
test
vaccin
human
therefor
latest
gener
dna
vaccin
reli
improv
deliveri
either
use
microparticl
viral
vector
particularli
promis
approach
heterolog
primeboost
strategi
administr
plasmid
dna
follow
recombin
viru
modifi
vaccinia
viru
ankara
mva
adenoviru
express
antigen
regimen
induc
strong
cell
respons
p
falciparum
adult
enhanc
respons
gambian
men
constantli
expos
p
falciparum
although
partial
protect
challeng
differ
p
falciparum
strain
observ
signific
differ
infect
rate
found
gambian
trial
spite
setback
similar
regimen
shown
also
highli
immunogen
hbv
tuberculosi
hiv
vaccin
mva
express
mycobacterium
antigen
elicit
strong
cell
respons
induct
cell
consid
crucial
antitumor
immun
respons
huge
number
trial
present
conduct
test
dna
vaccin
regimen
anticanc
treatment
viral
vehicl
vaccinia
adenoviru
compar
load
dc
term
abil
overcom
establish
toler
induc
immun
respons
transgen
mous
model
viral
formul
abl
wherea
dc
requir
repeat
administr
tlr
agonist
irrelev
viru
remov
suppress
treg
cell
model
establish
toler
might
prove
use
test
success
vaccin
face
longterm
antigen
exposur
case
cancer
chronic
diseas
two
studi
analyz
detail
cell
respons
vaccin
recombin
canarypox
viru
express
melanomaspecif
cell
epitop
focus
blood
metastas
patient
complet
regress
studi
reconfirm
earlier
observ
frequenc
antitumor
cell
rel
high
although
vaccin
lead
slight
increas
vaccinespecif
cell
remain
small
fraction
total
antitumor
cell
contrast
cell
direct
epitop
contain
vaccin
repres
vast
major
antitumor
cell
frequenc
increas
blood
metastas
thu
appear
appropri
vaccin
regimen
ineffici
preexist
specif
cell
combat
tumor
revers
indirect
manner
presum
activ
anoth
subset
cell
remain
clarifi
howev
much
reactiv
due
action
vaccineinduc
cell
much
gener
antigenindepend
immuneenhanc
effect
case
develop
therapeut
vaccin
vital
understand
balanc
tip
back
state
toler
success
immun
respons
develop
vaccin
aim
polysaccharid
ps
capsul
bacteria
one
great
achiev
vaccinolog
far
ps
use
largescal
vaccin
product
purifi
pathogen
grown
larg
quantiti
approach
costli
difficult
control
great
simplif
carbohydr
chemistri
involv
verezbencomo
et
al
demonstr
first
largescal
product
antihaemophilu
influenza
type
b
vaccin
consist
synthet
ps
conjug
tetanu
toxoid
protein
carrier
vaccin
shown
effici
commerci
avail
vaccin
induc
protect
level
antibodi
titer
infant
entir
synthet
vaccin
branch
structur
contain
ligand
cell
epitop
either
cell
b
cell
epitop
shown
elicit
strong
cell
b
cell
respons
respect
minim
requir
effici
vaccin
met
singl
molecul
target
activ
dc
cell
help
activ
antigenspecif
cell
b
cell
world
vaccin
undergo
dramat
chang
never
sophist
techniqu
indepth
knowledg
immunolog
process
hand
exploit
fulli
potenti
protect
well
cure
diseas
vaccin
formid
task
futur
develop
effect
therapeut
vaccin
situat
chronic
antigen
exposur
elicit
suffici
strong
immun
respons
case
cancer
chronic
infecti
diseas
compar
vaccin
selflimit
infect
aim
good
real
pathogen
less
harm
requir
develop
vaccin
better
natur
antigen
induc
immun
knowledg
necessari
succeed
challeng
recent
articl
describ
use
multigenom
analysi
screen
larg
panel
strain
identifi
univers
group
b
streptococcu
vaccin
although
none
singl
antigen
contain
vaccin
elicit
protect
strain
combin
four
protein
abl
cover
wide
rang
strain
mueller
ak
labai
kapp
sh
matuschewski
k
genet
modifi
plasmodium
parasit
protect
experiment
malaria
vaccin
natur
studi
revers
genet
use
gener
plasmodium
knockout
strain
development
block
earli
liver
stage
use
live
attenu
vaccin
malaria
mous
model
strain
confer
protect
infecti
sporozoit
challeng
